Margin dodolan resik: Assembly Biosciences (ASMB)

Simbol resmi perusahaan Assembly Bio (ASMB)

Assembly Biosciences is developing a therapy system for viral liver pathologies, aiming for the complete eradication of hepatitis B. The net profit margin on the GURU.Markets terminal chart demonstrates volatility, where the -16.60 indicator determines the parameter status. The business relies on the development of small molecules amidst patent wars, while its moat is formed by strict FDA control.

Rentabilitas dodolan miturut bathi resik Assembly Corp (ASMB): kanggo periode 04.07.2022 - 19.11.2026

Rincian metrik keuangan lan pasar Assembly Biosciences (ASMB)

- nilai pasar lan prakiraan target analis:
Analisis komprehensif perusahaan:Assembly Biosciences, Inc., ASMB
Produk asil prodhuksi Assembly Corp

Assessing the financial stability of Assembly Biosciences (ASMB) requires an analysis of the company's ability to generate net profit from every dollar of revenue during the transformation of its virology portfolio. This net profit margin ratio on GURU.Markets reflects the remaining funds after covering all operating and tax expenses, allowing investors to differentiate a temporary margin decline during R&D scaling from a systemic business model crisis.